Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03228667 · ClinicalTrials.gov registry record · Phase 2
QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors
A Phase 2 study of Non-Small Cell Lung Cancer and Melanoma, sponsored by ImmunityBio.
- Active
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
- 20
- Study locations
NCT03228667 is a Phase 2 study of Non-Small Cell Lung Cancer and Melanoma that is active but no longer recruiting, run by ImmunityBio. The registered enrollment target is 40 participants, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (94% lower). The trial reports 20 study locations across 11 states.
The verdict
NCT03228667, a Phase 2 study of Non-Small Cell Lung Cancer and Melanoma, is active but no longer recruiting, sponsored by ImmunityBio.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
- 20
- Study locations
Study Summary
QUILT-3.055 is a Phase 2b, open-label, multicohort study investigating combination immunotherapies in patients with advanced solid tumors who have previously been treated with PD-1/PD-L1 checkpoint inhibitors. The study aims to evaluate the safety and efficacy of NAI (nogapendekin alfa inbakicept) in combination with other agents like checkpoint inhibitors and cell therapies across various cancer types and treatment settings. The study includes multiple cohorts based on prior therapies and cancer types, with a focus on assessing overall response rate (ORR), overall survival (OS), and other measures of anti-tumor activity and immune response.
Conditions Studied
Interventions
- DRUG N-803 + Pembrolizumab
- DRUG N-803 + Nivolumab
- DRUG N-803 + Atezolizumab
- DRUG N-803 + Avelumab
- DRUG N-803 + Durvalumab
Study Locations (20)
California
- Chan Soon-Shiong Institute for Medicine - El Segundo
- MemorialCare Health System - Fountain Valley
- Glendale Adventist Medical Center - Glendale
- University of Southern California Norris Comprehensive Cancer Center - Los Angeles
- Desert Hematology Oncology Medical Group, Inc. - Rancho Mirage
Florida
- Memorial Healthcare System - Hollywood
- Miami Cancer Institute (Baptist Health South Florida) - Miami
- University of Miami - Miami
Missouri
- Mercy Research Joplin - Joplin
- Mercy Clinic Cancer & Hematology - Chub O'Reilly Cancer Center - Springfield
- Washington University School of Medicine - St Louis
Kentucky
- Baptist Health - Lexington - Lexington
- Baptist Health- Louisville - Louisville
Alaska
- Alaska Clinical Research Center - Anchorage
Arkansas
- Genesis Cancer Center - Hot Springs
Indiana
- Horizon Oncology Associates - Lafayette
Iowa
- University of Iowa Holden Comprehensive Cancer Center - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2018-12-11 |
| Est. Completion | 2030-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03228667
The ClinicalTrials.gov registry entry for NCT03228667 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (94% lower). The listed sponsor is ImmunityBio, which has 46 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 5 interventions - of which N-803 + Pembrolizumab is the first listed.
NCT03228667 reports 20 study locations spanning 11 distinct geographic areas - top geographies include California, Florida, Missouri.
Frequently Asked Questions
What is clinical trial NCT03228667 about?
NCT03228667 is a clinical study titled "QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors". QUILT-3.055 is a Phase 2b, open-label, multicohort study investigating combination immunotherapies in patients with advanced solid tumors who have previously been treated with PD-1/PD-L1 checkpoint inhibitors. The study aims to evaluate the safety and efficacy of NAI (nogapendekin alfa inbakicept) i...
What is the current status of trial NCT03228667?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2018-12-11. Estimated completion is 2030-12-31.
What conditions does trial NCT03228667 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Melanoma, Gastric Cancer, Cervical Cancer, Hepatocellular Carcinoma.
What interventions are being tested in trial NCT03228667?
The interventions under investigation include: N-803 + Pembrolizumab (DRUG), N-803 + Nivolumab (DRUG), N-803 + Atezolizumab (DRUG), N-803 + Avelumab (DRUG), N-803 + Durvalumab (DRUG).
Who is sponsoring clinical trial NCT03228667?
This trial is sponsored by ImmunityBio, which has 46 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03228667 being conducted?
This trial has 20 study locations across Alaska, Arkansas, California, Florida, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RECRUITING · Phase 2
-
Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
RECRUITING · Phase 2
-
A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.